Key Takeaways:
- Pfizer's strategic focus on acquisitions aims to boost its cardiometabolic offerings.
- Analysts suggest an average upside potential of over 24% for Pfizer stock.
- Despite recent challenges, Pfizer's earnings exceeded expectations, maintaining a "Hold" recommendation.
Pfizer Inc. (NYSE: PFE) is actively seeking acquisitions or partnerships to strengthen its cardiometabolic portfolio, following a setback in its weight loss program. This strategic move comes on the heels of an 8% decline in quarterly revenue, largely attributed to underwhelming sales of Paxlovid. However, Pfizer surprised the market by surpassing earnings expectations and reaffirming its financial guidance.
Wall Street Analysts' Forecast
According to predictions from 19 analysts, the average one-year price target for Pfizer Inc. (PFE, Financial) is set at $28.71. This forecast presents a noteworthy range, with high estimates reaching $41.43 and low estimates at $22.00. The average target suggests a substantial upside potential of 24.54% compared to the current stock price of $23.05. For more in-depth estimates, visit the Pfizer Inc (PFE) Forecast page.
The consensus rating from 23 brokerage firms for Pfizer Inc. (PFE, Financial) stands at 2.6 on a five-point scale, corresponding to a "Hold" status. This scale ranges from 1, indicating a Strong Buy, to 5, meaning Sell.
Based on GuruFocus metrics, Pfizer Inc.'s (PFE, Financial) estimated GF Value for the next year is $28.58. This estimation signals a potential upside of 23.99% from the current trading price of $23.05. The GF Value is GuruFocus' calculation of the intrinsic value a stock should trade for, derived from historical trading multiples, previous growth data, and future business performance projections. For detailed data, refer to the Pfizer Inc (PFE) Summary page.
